Tomoko Hayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tomoko Hayashi has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
Shiyin Yao
UC San Diego Moores Cancer Center, University of California San Diego, 9500 Gilam Dr., La Jolla, California 92093, United States
17 shared publicationsMichael Chan
UC San Diego Moores Cancer Center, University of California San Diego, 9500 Gilam Dr., La Jolla, California 92093, United States
14 shared publicationsDennis A. Carson
Department of Medicine, University of California San Diego, 9500 Gilam Dr., La Jolla, California 92093, United States
13 shared publicationsHoward B. Cottam
Department of Medicine, University of California San Diego, 9500 Gilam Dr., La Jolla, California 92093, United States
13 shared publications- Dennis A. Carson
Department of Medicine, University of California, San Diego, United States
10 shared publications Maripat Corr
Department of Medicine, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0809, USA
10 shared publications
Latest Publications
- 13 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6490-6507
Structure–Activity Relationship Studies in Substituted Oxadiazoles as Inducers of Extracellular Vesicles
We characterized small-molecule compounds discovered through a prior high-throughput screening campaign that enhanced the release of immunostimulatory extracellular vesicles (EVs) and identified compound #645 (compound 1) as an immunomodulatory compound. Here, we performed systematic structure-activity relationship (SAR) studies to probe the scaffold for analogs inducing tetraspanin (CD63) reporter activity, a marker of EV biogenesis and release, in human THP-1 cells. A potent analog 39 was identified, which also stimulated the expression of an immunostimulatory cytokine and costimulatory molecules by antigen-presenting cells and promoted antigen cross-presentation to CD8+ T cells. As its mechanism of action, compound 39 was found to interfere with tubulin polymerization, possibly binding to the nocodazole binding site on beta-tubulin as evident by molecular docking studies. Additionally, 39 preferentially impaired the viability in proliferating cells and may be a potential therapeutic agent for cancer and immunotherapy applications.
- 13 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6490-6507
Structure–Activity Relationship Studies in Substituted Oxadiazoles as Inducers of Extracellular Vesicles
We characterized small-molecule compounds discovered through a prior high-throughput screening campaign that enhanced the release of immunostimulatory extracellular vesicles (EVs) and identified compound #645 (compound 1) as an immunomodulatory compound. Here, we performed systematic structure-activity relationship (SAR) studies to probe the scaffold for analogs inducing tetraspanin (CD63) reporter activity, a marker of EV biogenesis and release, in human THP-1 cells. A potent analog 39 was identified, which also stimulated the expression of an immunostimulatory cytokine and costimulatory molecules by antigen-presenting cells and promoted antigen cross-presentation to CD8+ T cells. As its mechanism of action, compound 39 was found to interfere with tubulin polymerization, possibly binding to the nocodazole binding site on beta-tubulin as evident by molecular docking studies. Additionally, 39 preferentially impaired the viability in proliferating cells and may be a potential therapeutic agent for cancer and immunotherapy applications.
- 13 November 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (47) , 64135-64148
Liposomal Oncolytic Adenovirus Enables Efficient CAR-Independent Transduction of Tumors and Enhances NK Cell-Mediated Abscopal Responses
Effective delivery of oncolytic adenoviruses to tumors with low coxsackievirus and adenovirus receptor (CAR) expression remains a major barrier in oncolytic virotherapy. In this study, a liposome-encapsulated adenovirus serotype 5-based platform (DfA) was designed to bypass CAR-dependent transduction, presenting engaging antitumor immune responses in an innate immune, NK cell-dependent manner. The results show that DfA efficiently transduces CAR-low murine colorectal cancer cells (CT26) and triggers the release of damage-associated molecular patterns (DAMPs), including ATP, HMGB1, and calreticulin. In immunocompetent mice, intratumoral DfA treatment suppressed both local and distant tumor growth. In nude mice lacking T cells, DfA retained systemic antitumor activity, but abscopal effects were lost upon NK cell depletion, which suggests that natural killer (NK) cells are essential mediators of this response. In vitro, DfA enhanced NK92 cytotoxicity against low-CAR MCF-7 breast cancer cells, which further supports its innate immune-activating potential. Together, these findings reveal a previously unrecognized role for NK cells in mediating adenovirus-induced abscopal effects and position DfA as a clinically actionable strategy for CAR-deficient tumors.
- 13 November 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (47) , 64135-64148
Liposomal Oncolytic Adenovirus Enables Efficient CAR-Independent Transduction of Tumors and Enhances NK Cell-Mediated Abscopal Responses
Effective delivery of oncolytic adenoviruses to tumors with low coxsackievirus and adenovirus receptor (CAR) expression remains a major barrier in oncolytic virotherapy. In this study, a liposome-encapsulated adenovirus serotype 5-based platform (DfA) was designed to bypass CAR-dependent transduction, presenting engaging antitumor immune responses in an innate immune, NK cell-dependent manner. The results show that DfA efficiently transduces CAR-low murine colorectal cancer cells (CT26) and triggers the release of damage-associated molecular patterns (DAMPs), including ATP, HMGB1, and calreticulin. In immunocompetent mice, intratumoral DfA treatment suppressed both local and distant tumor growth. In nude mice lacking T cells, DfA retained systemic antitumor activity, but abscopal effects were lost upon NK cell depletion, which suggests that natural killer (NK) cells are essential mediators of this response. In vitro, DfA enhanced NK92 cytotoxicity against low-CAR MCF-7 breast cancer cells, which further supports its innate immune-activating potential. Together, these findings reveal a previously unrecognized role for NK cells in mediating adenovirus-induced abscopal effects and position DfA as a clinically actionable strategy for CAR-deficient tumors.
- 8 August 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (16) , 13703-13722
Structure–Activity Relationship Studies in Benzothiadiazoles as Novel Vaccine Adjuvants
Extracellular vesicles (EVs) can transfer antigens and immunomodulatory molecules, and such EVs released by antigen-presenting cells equipped with immunostimulatory functions have been utilized for vaccine formulations. A prior high-throughput screening campaign led to the identification of compound 634 (1), which enhanced EV release and increased intracellular Ca2+ influx. Here, we performed systematic structure-activity relationship (SAR) studies to investigate the scaffold for its potency as a vaccine adjuvant. Synthesized compounds were analyzed in vitro for CD63 reporter activity (a marker for EV biogenesis) in human THP-1 cells, induction of Ca2+ influx, IL-12 production, and cell viability in murine bone-marrow-derived dendritic cells. The SAR studies indicated that the ester functional group was requisite, and the sulfur atom of the benzothiadiazole ring replaced with a higher selenium atom (9f) or a bioisosteric ethenyl group (9h) retained potency. Proof-of-concept vaccination studies validated the potency of the selected compounds as novel vaccine adjuvants.
- 8 August 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (16) , 13703-13722
Structure–Activity Relationship Studies in Benzothiadiazoles as Novel Vaccine Adjuvants
Extracellular vesicles (EVs) can transfer antigens and immunomodulatory molecules, and such EVs released by antigen-presenting cells equipped with immunostimulatory functions have been utilized for vaccine formulations. A prior high-throughput screening campaign led to the identification of compound 634 (1), which enhanced EV release and increased intracellular Ca2+ influx. Here, we performed systematic structure-activity relationship (SAR) studies to investigate the scaffold for its potency as a vaccine adjuvant. Synthesized compounds were analyzed in vitro for CD63 reporter activity (a marker for EV biogenesis) in human THP-1 cells, induction of Ca2+ influx, IL-12 production, and cell viability in murine bone-marrow-derived dendritic cells. The SAR studies indicated that the ester functional group was requisite, and the sulfur atom of the benzothiadiazole ring replaced with a higher selenium atom (9f) or a bioisosteric ethenyl group (9h) retained potency. Proof-of-concept vaccination studies validated the potency of the selected compounds as novel vaccine adjuvants.
- Open Access
- 11 April 2023
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 18 (4) , 982-993
Identification of a Novel Small Molecule That Enhances the Release of Extracellular Vesicles with Immunostimulatory Potency via Induction of Calcium Influx
- 11 April 2023
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 18 (4) , 982-993
Open AccessIdentification of a Novel Small Molecule That Enhances the Release of Extracellular Vesicles with Immunostimulatory Potency via Induction of Calcium Influx
- Open Access
A Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination
Systemically vaccinated individuals against COVID-19 and influenza may continue to support viral replication and shedding in the upper airways, contributing to the spread of infections. Thus, a vaccine regimen that enhances mucosal immunity in the respiratory mucosa is needed to prevent a pandemic. Intranasal/pulmonary (IN) vaccines can promote mucosal immunity by promoting IgA secretion at the infection site. Here, we demonstrate that an intramuscular (IM) priming-IN boosting regimen with an inactivated influenza A virus adjuvanted with the liposomal dual TLR4/7 adjuvant (Fos47) enhances systemic and local/mucosal immunity. The IN boosting with Fos47 (IN-Fos47) enhanced antigen-specific IgA secretion in the upper and lower respiratory tracts compared to the IM boosting with Fos47 (IM-Fos47). The secreted IgA induced by IN-Fos47 was also cross-reactive to multiple influenza virus strains. Antigen-specific tissue-resident memory T cells in the lung were increased after IN boosting with Fos47, indicating that IN-Fos47 established tissue-resident T cells. Furthermore, IN-Fos47 induced systemic cross-reactive IgG antibody titers comparable to those of IM-Fos47. Neither local nor systemic reactogenicity or adverse effects were observed after IN delivery of Fos47. Collectively, these results indicate that the IM/IN regimen with Fos47 is safe and provides both local and systemic anti-influenza immune responses.
Open AccessA Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination
Systemically vaccinated individuals against COVID-19 and influenza may continue to support viral replication and shedding in the upper airways, contributing to the spread of infections. Thus, a vaccine regimen that enhances mucosal immunity in the respiratory mucosa is needed to prevent a pandemic. Intranasal/pulmonary (IN) vaccines can promote mucosal immunity by promoting IgA secretion at the infection site. Here, we demonstrate that an intramuscular (IM) priming-IN boosting regimen with an inactivated influenza A virus adjuvanted with the liposomal dual TLR4/7 adjuvant (Fos47) enhances systemic and local/mucosal immunity. The IN boosting with Fos47 (IN-Fos47) enhanced antigen-specific IgA secretion in the upper and lower respiratory tracts compared to the IM boosting with Fos47 (IM-Fos47). The secreted IgA induced by IN-Fos47 was also cross-reactive to multiple influenza virus strains. Antigen-specific tissue-resident memory T cells in the lung were increased after IN boosting with Fos47, indicating that IN-Fos47 established tissue-resident T cells. Furthermore, IN-Fos47 induced systemic cross-reactive IgG antibody titers comparable to those of IM-Fos47. Neither local nor systemic reactogenicity or adverse effects were observed after IN delivery of Fos47. Collectively, these results indicate that the IM/IN regimen with Fos47 is safe and provides both local and systemic anti-influenza immune responses.
- 2 June 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (23)
Mitochondria-dependent synthetic small-molecule vaccine adjuvants for influenza virus infection
Significance: Effective vaccine strategies are needed to overcome genetic, physiologic, or age-related deficits in immune responses relevant to vulnerable populations. Vaccine adjuvants that overcome these variants and do not compromise safety are highly desirable. We identified a synthetic small-molecule compound 81 [ N -(4-chloro-2,5-dimethoxyphenyl)-4-ethoxybenzenesulfonamide] and its derivative 2F52 [ N -benzyl- N -(4-chloro-2,5-dimethoxyphenyl)-4-ethoxybenzenesulfonamide] as activators of innate immunity via mitochondrial stress pathways, circumventing classic pathogen-recognition receptors. Neither 81 nor 2F52 as adjuvants caused local or systemic toxicity in mice after injection. Moreover, in a mouse influenza challenge study, compound 2F52 demonstrated protective effects when used with inactivated virus. Thus, compound 2F52, acting through an unconventional pathway to stimulate innate immunity, could be a useful synthetic adjuvant to enhance current and future vaccines.
- 2 June 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (23)
Mitochondria-dependent synthetic small-molecule vaccine adjuvants for influenza virus infection
Significance: Effective vaccine strategies are needed to overcome genetic, physiologic, or age-related deficits in immune responses relevant to vulnerable populations. Vaccine adjuvants that overcome these variants and do not compromise safety are highly desirable. We identified a synthetic small-molecule compound 81 [ N -(4-chloro-2,5-dimethoxyphenyl)-4-ethoxybenzenesulfonamide] and its derivative 2F52 [ N -benzyl- N -(4-chloro-2,5-dimethoxyphenyl)-4-ethoxybenzenesulfonamide] as activators of innate immunity via mitochondrial stress pathways, circumventing classic pathogen-recognition receptors. Neither 81 nor 2F52 as adjuvants caused local or systemic toxicity in mice after injection. Moreover, in a mouse influenza challenge study, compound 2F52 demonstrated protective effects when used with inactivated virus. Thus, compound 2F52, acting through an unconventional pathway to stimulate innate immunity, could be a useful synthetic adjuvant to enhance current and future vaccines.
- Open Access
- 16 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Generation and Application of a Reporter Cell Line for the Quantitative Screen of Extracellular Vesicle Release
Extracellular vesicles (EVs) are identified as mediators of intercellular communication and cellular regulation. In the immune system, EVs play a role in antigen presentation as a part of cellular communication. To enable drug discovery and characterization of compounds that affect EV biogenesis, function, and release in immune cells, we developed and characterized a reporter cell line that allows the quantitation of EVs shed into culture media in phenotypic high-throughput screen (HTS) format. Tetraspanins CD63 and CD9 were previously reported to be enriched in EVs; hence, a construct with dual reporters consisting of CD63-Turbo-luciferase (Tluc) and CD9-Emerald green fluorescent protein (EmGFP) was engineered. This construct was transduced into the human monocytic leukemia cell line, THP-1. Cells expressing the highest EmGFP were sorted by flow cytometry as single cell, and clonal pools were expanded under antibiotic selection pressure. After four passages, the green fluorescence dimmed, and EV biogenesis was then tracked by luciferase activity in culture supernatants. The Tluc activities of EVs shed from CD63Tluc-CD9EmGFP reporter cells in the culture supernatant positively correlated with the concentrations of released EVs measured by nanoparticle tracking analysis. To examine the potential for use in HTS, we first miniaturized the assay into a robotic 384-well plate format. A 2210 commercial compound library (Maybridge) was then screened twice on separate days, for the induction of extracellular luciferase activity. The screening data showed high reproducibility on days 1 and 2 (78.6%), a wide signal window, and an excellent Z′ factor (average of 2-day screen, 0.54). One hundred eighty-seven compounds showed a response ratio that was 3SD above the negative controls in both day 1 and 2 screens and were considered as hit candidates (approximately 10%). Twenty-two out of 40 re-tested compounds were validated. These results indicate that the performance of CD63Tluc-CD9EmGFP reporter cells is reliable, reproducible, robust, and feasible for HTS of compounds that regulate EV release by the immune cells.
- 16 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessGeneration and Application of a Reporter Cell Line for the Quantitative Screen of Extracellular Vesicle Release
Extracellular vesicles (EVs) are identified as mediators of intercellular communication and cellular regulation. In the immune system, EVs play a role in antigen presentation as a part of cellular communication. To enable drug discovery and characterization of compounds that affect EV biogenesis, function, and release in immune cells, we developed and characterized a reporter cell line that allows the quantitation of EVs shed into culture media in phenotypic high-throughput screen (HTS) format. Tetraspanins CD63 and CD9 were previously reported to be enriched in EVs; hence, a construct with dual reporters consisting of CD63-Turbo-luciferase (Tluc) and CD9-Emerald green fluorescent protein (EmGFP) was engineered. This construct was transduced into the human monocytic leukemia cell line, THP-1. Cells expressing the highest EmGFP were sorted by flow cytometry as single cell, and clonal pools were expanded under antibiotic selection pressure. After four passages, the green fluorescence dimmed, and EV biogenesis was then tracked by luciferase activity in culture supernatants. The Tluc activities of EVs shed from CD63Tluc-CD9EmGFP reporter cells in the culture supernatant positively correlated with the concentrations of released EVs measured by nanoparticle tracking analysis. To examine the potential for use in HTS, we first miniaturized the assay into a robotic 384-well plate format. A 2210 commercial compound library (Maybridge) was then screened twice on separate days, for the induction of extracellular luciferase activity. The screening data showed high reproducibility on days 1 and 2 (78.6%), a wide signal window, and an excellent Z′ factor (average of 2-day screen, 0.54). One hundred eighty-seven compounds showed a response ratio that was 3SD above the negative controls in both day 1 and 2 screens and were considered as hit candidates (approximately 10%). Twenty-two out of 40 re-tested compounds were validated. These results indicate that the performance of CD63Tluc-CD9EmGFP reporter cells is reliable, reproducible, robust, and feasible for HTS of compounds that regulate EV release by the immune cells.
- 2 March 2021
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 4 (3) , 2732-2741
Glyco-Nanoadjuvants: Sugar Structures on Carriers of a Small Molecule TLR7 Ligand Affect Their Immunostimulatory Activities
Toll-like receptors (TLRs) are pattern recognition receptors that activate innate immunity, and their ligands are promising adjuvants for vaccines and immunotherapies. Small molecule TLR7 ligands are ideal vaccine adjuvants as they induce not only proinflammatory cytokines but also type I interferons. However, their application has only been approved for local administration due to severe systemic immune-related adverse events. In a previous study, we prepared the gold nanoparticles coimmobilized with synthetic small molecule TLR7 ligand, 1V209, and α-mannose (1V209-αMan-GNPs). 1V209-αMan-GNPs were selectively delivered via a cell surface sugar-binding protein, mannose receptor, which enabled selective delivery of TLR7 ligands to immune cells. Besides the mannose receptor, immune cells express various sugar-binding proteins such as macrophage galactose binding lectins and sialic acid-binding immunoglobulin-type lectins and recognize distinct sugar structures. Hence, in the present study, we investigated whether sugar structures on GNPs affect the efficiency and selectivity of intracellular delivery and subsequent immunostimulatory potencies. Five neutral sugars and two sialosides were selected and each sugar was coimmobilized with 1V209 onto GNPs (1V209-SGNPs) and their innate immunostimulatory potencies were compared to that of 1V209-αMan-GNPs. The in vitro study using mouse bone marrow derived dendritic cells (BMDCs) demonstrated that α-glucose, α-N-acetylglucosamine, or α-fucose immobilized 1V209-SGNPs increased interleukin-6 and type I interferon release similar to that of 1V209-αMan-GNPs, whereas galacto-type sugar immobilized 1V209-SGNPs predominantly enhanced type I interferon release. In contrast, sialoside immobilized 1V209-SGNPs did not enhance the potency of 1V209. In the in vivo immunization study using ovalbumin as a model antigen, neutral sugar immobilized 1V209-SGNPs induced comparable T helper-1 immune response to that of 1V209-αMan-GNPs and by 10-fold higher than that of sialoside immobilized 1V209-SGNPs. These results indicate that the sugar structures on 1V209-SGNPs affect their immunostimulatory activities, and functionalization of the carrier particles is important to shape immune responses.
- 2 March 2021
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 4 (3) , 2732-2741
Glyco-Nanoadjuvants: Sugar Structures on Carriers of a Small Molecule TLR7 Ligand Affect Their Immunostimulatory Activities
Toll-like receptors (TLRs) are pattern recognition receptors that activate innate immunity, and their ligands are promising adjuvants for vaccines and immunotherapies. Small molecule TLR7 ligands are ideal vaccine adjuvants as they induce not only proinflammatory cytokines but also type I interferons. However, their application has only been approved for local administration due to severe systemic immune-related adverse events. In a previous study, we prepared the gold nanoparticles coimmobilized with synthetic small molecule TLR7 ligand, 1V209, and α-mannose (1V209-αMan-GNPs). 1V209-αMan-GNPs were selectively delivered via a cell surface sugar-binding protein, mannose receptor, which enabled selective delivery of TLR7 ligands to immune cells. Besides the mannose receptor, immune cells express various sugar-binding proteins such as macrophage galactose binding lectins and sialic acid-binding immunoglobulin-type lectins and recognize distinct sugar structures. Hence, in the present study, we investigated whether sugar structures on GNPs affect the efficiency and selectivity of intracellular delivery and subsequent immunostimulatory potencies. Five neutral sugars and two sialosides were selected and each sugar was coimmobilized with 1V209 onto GNPs (1V209-SGNPs) and their innate immunostimulatory potencies were compared to that of 1V209-αMan-GNPs. The in vitro study using mouse bone marrow derived dendritic cells (BMDCs) demonstrated that α-glucose, α-N-acetylglucosamine, or α-fucose immobilized 1V209-SGNPs increased interleukin-6 and type I interferon release similar to that of 1V209-αMan-GNPs, whereas galacto-type sugar immobilized 1V209-SGNPs predominantly enhanced type I interferon release. In contrast, sialoside immobilized 1V209-SGNPs did not enhance the potency of 1V209. In the in vivo immunization study using ovalbumin as a model antigen, neutral sugar immobilized 1V209-SGNPs induced comparable T helper-1 immune response to that of 1V209-αMan-GNPs and by 10-fold higher than that of sialoside immobilized 1V209-SGNPs. These results indicate that the sugar structures on 1V209-SGNPs affect their immunostimulatory activities, and functionalization of the carrier particles is important to shape immune responses.